S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
North Carolina medical marijuana sales begin at Cherokee store
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
North Carolina medical marijuana sales begin at Cherokee store
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
North Carolina medical marijuana sales begin at Cherokee store
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
North Carolina medical marijuana sales begin at Cherokee store
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

$8.97
-0.51 (-5.38%)
(As of 04/19/2024 ET)
Today's Range
$8.91
$9.88
50-Day Range
$6.21
$12.05
52-Week Range
$6.07
$17.02
Volume
590,237 shs
Average Volume
865,061 shs
Market Capitalization
$524.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Phathom Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
137.8% Upside
$21.33 Price Target
Short Interest
Bearish
39.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Phathom Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$30.19 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.22) to ($3.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

Medical Sector

613th out of 909 stocks

Pharmaceutical Preparations Industry

271st out of 425 stocks

PHAT stock logo

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Stock Price History

PHAT Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.7%
12 Most Shorted Stocks in 2024
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 3%
SIGA Names Larry Miller General Counsel
See More Headlines
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/21/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
452
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.33
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+137.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-201,590,000.00
Pretax Margin
-29,558.95%

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
($1.27) per share

Miscellaneous

Free Float
42,664,000
Market Cap
$524.92 million
Optionable
Optionable
Beta
0.63
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


PHAT Stock Analysis - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHAT shares.
View PHAT analyst ratings
or view top-rated stocks.

What is Phathom Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Phathom Pharmaceuticals' stock. Their PHAT share price targets range from $10.00 to $28.00. On average, they expect the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 137.8% from the stock's current price.
View analysts price targets for PHAT
or view top-rated stocks among Wall Street analysts.

How have PHAT shares performed in 2024?

Phathom Pharmaceuticals' stock was trading at $9.13 at the beginning of 2024. Since then, PHAT shares have decreased by 1.8% and is now trading at $8.97.
View the best growth stocks for 2024 here
.

When is Phathom Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PHAT earnings forecast
.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its earnings results on Thursday, March, 7th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.12. The business earned $0.68 million during the quarter, compared to analysts' expectations of $0.93 million. During the same period in the previous year, the company posted ($1.33) earnings per share.

What ETFs hold Phathom Pharmaceuticals' stock?

ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Medicxi Ventures Management Jersey Ltd (12.76%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran.
View institutional ownership trends
.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners